Policy / Pricing A ‘hijacked plane’: CDC, under RFK Jr.’s influence, trades science for dogma BioPharma DiveA series of controversial policy changes directed by the HHS secretary have left experts fearful of the future implications for public health.Policy / PricingRead full story pharminent April 1, 2026 (Last updated: April 1, 2026) BioPharma Dive A series of controversial policy changes directed by the HHS secretary have left experts fearful of the future implications for public health. Policy / PricingRead full story Please leave this field emptySign up to receive free daily digest Check your inbox or spam folder to confirm your subscription. Post navigation Previous: Agios mulls early FDA filing for sickle cell therapyNext: FDA, after turbulent year, leaves drugmakers guessing on its direction Related Stories Policy / Pricing US generic tariff reprieve on the rocks as Trump proposes 100% rate in 2028 pharminent July 22, 2026 Policy / Pricing UK commits to pharma IP protection in Swiss trade deal pharminent July 16, 2026 Policy / Pricing Germany approves healthcare costs overhaul despite significant pharma opposition pharminent July 13, 2026
